Clinical impact of rapid drug susceptibility testing to accompany fluoroquinolone-containing universal tuberculosis regimens: a markov model

Future first-line tuberculosis treatment may include fluoroquinolones and/or require testing for fluoroquinolone susceptibility. We use a quantitative model to

Saved in:

Bibliographic Details
Main Authors:	Kendall, Emily A. (Author) , Malhotra, Shelly (Author) , Cook-Scalise, Sarah (Author) , Dowdy, David W. (Author) , Denkinger, Claudia M. (Author)
Format:	Article (Journal)
Language:	English
Published:	1 December 2020
In:	Clinical infectious diseases Year: 2020, Volume: 71, Issue: 11, Pages: 2889-2896
ISSN:	1537-6591
DOI:	10.1093/cid/ciz1179
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/cid/ciz1179 Verlag, lizenzpflichtig, Volltext: https://academic.oup.com/cid/article/doi/10.1093/cid/ciz1179/5669959
Author Notes:	Emily A. Kendall, Shelly Malhotra, Sarah Cook-Scalise, David W. Dowdy, Claudia M. Denkinger

Description
Summary:	Future first-line tuberculosis treatment may include fluoroquinolones and/or require testing for fluoroquinolone susceptibility. We use a quantitative model to
Item Description:	Published online December 9, 2019 Gesehen am 17.07.2020
Physical Description:	Online Resource
ISSN:	1537-6591
DOI:	10.1093/cid/ciz1179